Stay tuned for IOLC 2019 Agenda Information
2018 Conference Agenda
November 4, 2018
1:30PM - 2:30PM Registration Desk Open
2:30PM Depart for Humanitas Cancer Center
(visit & transportation included in registration fee)
3:00PM - 4:30PM Humanitas Cancer Center Tour - Led by Camille Grosso, Cancer Center Manager, Humanitas Research Hospital
5:00PM - 6:00PM Welcoming Reception at Hotel Excelsior Gallia
November 5, 2018
8:00AM Registration Desk Open
8:00AM - 9:00AM Networking with Cafe & Cornetto
9:00AM - 10:00AM Session #1
Bending the Cost and Quality Curve – How Nations judge their Clinical Quality of Care
Speaker: Stefano Cazzaniga, Principal, Boston Consulting Group
10:00AM - 11:00AM Session #2
Economics of Cancer Care: Access to Budgetary Decisions and Negotiations related to Pharmaceutical Pricing
Speaker: Philip Schwieterman PharmD, MHA, UK HealthCare and Markey Cancer Center
This session will discuss current and future trends of oncology drug pricing in the United States along with how rising drug prices are affecting patients, providers, and payers. Session will also identify various pricing and payment methodologies impacting oncology practices and opportunities to address them.
11:00AM - 11:30AM Networking Break
11:30AM - 12:30PM Session #3
Precision data - bridging the gap between clinical and payer value in Value Based Healthcare
Speaker: Matt Hickey, Intacare International Limited
An exploration of how precision data can be used to correlate clinical outcomes and cost data to enable and thereafter showcase improved efficiency, affordability value - viewed from the perspective of multiple stakeholders (patients, clinicians, clinical service providers, payers, pharma, academia and R&D)
12:30PM - 2:00PM Lunch and Explore Milan (On Your Own)
2:00PM - 3:00PM Session #4
The United Nations of Oncology: How Sarah Cannon has brought together programs, people, processes and places to form a united front in the fight against cancer
Speaker: Rocky Billups, MS, Vice President of Operations, Sarah Cannon
In a world where oncology services, programs and approaches have historically been fragmented, Sarah Cannon has pioneered a better way of fighting cancer together. Forging partnerships, initiating collaborative work groups, establishing protocols and best practices to drive improved outcomes – we have brought a more unified approach the field of oncology research and care.
3:00PM - 3:30PM Networking Break
3:30PM - 5:00PM Session #5
Networking Opportunities and Pitfalls: A Tale of Four Cities
Speakers: Josep M Borras , Catalonian Cancer Plan, Department of Health and Biochemical Research, Institute of Bellvitge, University of Barcelona
Verdiana Morando, MsC, PhD, Associate Professor of Practice Management, SDA school of Management Bocconi University of Milan
Valeria D. Tozzi, Associate Professor of Practice of Government, Health and Not for Profit, SDA Bocconi School of Management
Didier Verhoeven, Guest Professor, University of Antwerp, Belgium
Rocky Billups, MS, Vice President of Operations, Sarah Cannon
Cancer networks have been developed across Europe to harmonise cancer care and integrate comprehensive cancer control. Networks have been set up at different levels presenting differences of governance, management structures and network maturity. Intensity of professional linkages influence clinical practice organization. Introduction of network governances remains critical. In this lecture strength and weaknesses will be discussed to improve clinical outcomes and network effectiveness. Coming from different countries and working with different network structures three experts will discuss challenges and opportunities. They will analyse the role and patterns of professional and multidisciplinary cooperation focusing on the role of collaborative networking in integrating cancer care processes and knowledge management between hospitals. Attendees will hear about the global and special vision from four cities: Antwerp, Barcelona, Dubai and Milan.
5:00PM - 6:00PM Aperitivo Hour Reception Hotel Excelsior Gallia
6:00PM Evening On Your Own
November 6, 2018
8:00AM Registration Desk Open
8:00AM - 9:00AM Networking with Cafe & Cornetto
9:00AM - 10:00AM Session #6
Clinical Trials and Recruitment
Part 1: Presented by Michele Tedeschi, MD, Istituto Clinico Humanitas and Prof. Carmello Carlo-Stella (Hematologist), Istituto Clinico Humanitas about Fase 1 studies focusing:
The clinical need to have a Fase I unit in terms of patients benefits
Fase I trials evolution in Italy, and Humanitas positioning in this national frame
Impacts of Fase I studies in managing resources
Time for studies activation and competition for recruitment
Part 2: Presented by Ollieta Nicholas, Department Administrator, Interventional Radiology, University of Texas MD Anderson Cancer Center, best practices in clinical trials from executive point of view:
10:00AM - 11:00AM Session #7
MD and Administrator Burnout
Speakers: Jane Welter, Deputy Director Administration Cancer Center, Mayo Clinic
Kimberly F. Kerstann, PhD, Sr. Director, Cancer Research Administration, Winship Cancer Institute, Emory University
11:00AM - 11:30AM Networking Break
11:30AM - 12:30PM Session #8
Innovations in Technology: Real-World Data and AI Predictalytics to Achieve at the Point of Care Decision Support
Speakers: Bob Gold, GoMo Health
Kevin Massoudi, MD Program Lead Digital Health EMEIA, Varian
12:30PM - 2:00PM Lunch and Explore Milan (On Your Own)
2:00PM - 2:45PM Session #9
Patient Satisfactory and Delivery – Measuring Outcomes
Speakers: Marco Albini, Quality Monitoring Office Head, Humanitas Cancer Center
Monica Porli, Patient Experience Chief Officer, Humanitas Cancer Center
During the last decade, the way cancer centers approach patient experience is radically changing, moving only cure to a complete take-care. Humanitas Cancer Center is adopting an innovative design thinking approach in order to redesign patient pathways and to measure outcomes and patient satisfactory all along patient journey. This includes to tackle several challenges :
What is value for patient and patient involvement
How do we involve patients and professionals to redesign the care and the cure
How do we measure outcomes and patient satisfactory
It is not only about measuring but also about giving feedback
This session will be focused on Breast cancer and Prostate cancer
2:45PM - 3:30PM Session #10
Rethinking Fight against Cancer from a Determinants of Health Approach
Speaker: Eduardo Missoni, Global Health and Development, Master of International Health MGMT Economics and Policy, SDA Bocconi Management School
The increase of non communicable diseases in general, and cancer in particular, since the mid of last century is related with changes in the way people are born, grow and age. In other words, this trend cannot be attributed exclusively to improved diagnosis, nor solely to ageing of world population. It correlates with the acceleration of globalization and the diffusion of the western development and life-style model. Adopting a determinants of health approach, my presentation will explore the role of the dominant modes of production, distribution and consumption of goods and services, which are mainly driven by profit and unsustainable economic growth goals. I argue that the response to cancer cannot be pursued merely through conventional biomedical approaches. Upstream social, economic and environmental causal processes need to be addressed, addressing societal drivers and implementing public for health policies in all sectors. A focus which also requires a strategic, thus “disruptive” rethinking of current approaches for prevention and therapy.
3:30PM Conference Adjourns
2017 IOLC Agenda
November 12, 2017
14:00 – 15:00 Welcome and Tour of University College Hospital Macmillan Cancer Centre
15:00 – 16:00 Roundtable Discussion (Informal Discussion)
Moderator - Dave Gosky, University of Kentucky - Markey Cancer Center
18:00 – 19:00 Welcoming Reception at Conrad St. James Hotel
November 13, 2017
8:00 - 8:15 Registration & Coffee/Tea Service
8:15 - 9:00 Oncology Program and Population Health: Closing the Gap
Speaker: Richard Wender, Chief Cancer Control Officer, American Cancer Society, Inc.
While the burden of cancer continues to increase around the world, age adjusted cancer mortality rates in higher resource nations have been declining for well over a decade. In the United States, mortality rates have fallen 26% since the 1990 mortality peak. Although average years of surviving a cancer diagnosis have grown for virtually every type of cancer, in adults, mortality declines are largely confined to those cancers for which we have a prevention and/or screening strategy. Tobacco control and increased screening have contributed to lower mortality rates for lung cancer, colon cancer, prostate cancer, and breast cancer, particularly in the United States, which has placed a higher emphasis on cancer screening than in many other nations. While hospital based cancer programs have traditionally engaged with patients and families at the point of diagnosis, a new vision is emerging for the role of these critical components of our health care delivery systems. A comprehensive cancer program will increasingly be expected to embrace population health and to catalyze improvements in care for the communities they serve. This talk will review the elements of this new population based approach to comprehensive cancer care.
9:15 – 10:15 Structuring Oncology Service Line Management for Success
Dave Gosky, University of Kentucky - Markey Cancer Center
Luciano Ravera, Humanitas Clinical Institute
This presentation will review leadership structures for an oncology service line that foster alignment with a hospital’s strategic plan to help drive clinical excellence and financial growth. The importance of governance and leadership, creating aligned relationships with physicians, and development of key teams will be discussed.
10:30 – 11:30 Innovations in Technology Discussion
Kevin Brown, Elekta
Luis Lasalvia, MD, Siemens Healthineers
Kevin Massoudi, Varian Medical Systems
Luis Lasalvia, MD, Siemens Healthineers will be delivering an executive perspective on 5 topics, and sharing the discussion on innovation and technologies.
How the transformation of healthcare is aiming to deliver excellent care, while being less expensive.
How medicine will be more precise.
How value will shape care delivery.
How patients will become informed consumers.
How digitalization will revolutionize the management of cancer
11:30 – 12:30 Bridging the gap between Health Care Sciences, Leadership, Medical Community and Real Life
Didier Verhoeven, MD, PhD, University of Antwerp
Claudia Allemani, Associate Professor of Cancer Epidemiology (Concord Programme), LSHMT
Didier Verhoeven is a “real clinician”, a medical oncologist, leading a breast unit in Belgium, a guest Professor at the University of Antwerp, trying to bridge the gap between health care sciences, the medical community and the real life.
Health care is a complex process with economical, cultural and ethical aspects.The institute of medicine (IOM) made following recommendations for delivering high quality cancer care : engaged patients, a quality workforce, evidence based cancer care,a well developed IT system, quality control including patient outcome and cost and a accessible cancer care.
Clinical leadership with commitment to improvement, the wish to solve problems and the culture in our hospitals plays an important role in a better outcome with less clinical variability.
Cancer policy and health system funding are focused on organizations, not on networking. Cancer networks are population-accountable systems based on a medical community working at different levels of clinical complexity. Clinicians lack of a specific framework and involvement may become a disincentive for working together with the hospitals making efforts in coordinating cancer services. Cooperation between physicians must be promoted as a necessary condition for succes.
A health policy with a good governance, participation of the medical experts, involvement of primary care and nursing , a structure with less competition between providers and a solution of financial pressures are crucial elements in the daily real life work.
12:30 – 14:00 Lunch (On Your Own)
14:00 – 14:45 Personalized Medicine & Genomics
Charles Swanton, The Francis Crick Institute
Genomics has transformed our understanding of disease and our ability to deliver care in a way that is specific and personal to each individual patient. Establishing the sequence of an individual’s genetic material means it is possible to identify sequences or mutations which are specific to that person. Not only can these sequences identify the cause or stage of disease, the risk of future disease, they can also help us to predict the likely benefits and side effects in response to a particular medication. This knowledge has the genuine potential to significantly change cancer treatments in the 21st century.
In this session we will summarize the current use and future potential of genomics and personalized medicine. We will explore how to embed its use in everyday clinical pathways for the benefit of both clinicians and patients.
14:45 – 15:30 Cancer treatment in the 21st Century:
Opportunities and Challenges from a Chief Executive’s Perspective
Professor Marcel Levi, Chief Executive,
University College London Hospitals NHS Foundation Trust (UCLH)
17:00 – 18:00 Networking Reception
November 14, 2017
8:00 - 8:30 Registration & Coffee/Tea Service
8:30 - 9:45 Tackling Access, Quality, and the Cost of Cancer Care Internationally
Linda Weller-Newcomb, PhD, Vice President, Lahey Health Cancer Institute
Matt Hickey, Director of Clinical Strategy, GenesisCare
Cancer is one of the leading causes of death and disease, with 14.1 million new cancer cases worldwide in 2012. By 2030, an estimated 23.6 million new cancer cases will occur worldwide. Forty percent of those cases occur in countries with a low or medium level of Human Development Index.[i] In the U.S., the Institute of Medicine, ASCO, ACoS, and NCCN are adopting policy positions that address access, effectiveness, efficiency, clinical benefit, equity, and cost of cancer care. While most professional organizations have historically remained silent on the costs of cancer care, there is increasing focus on the topics of access, cost, clinical benefit, and toxicity associated with new drug developments. The unsustainable rising cost of cancer drugs is a major concern of cancer programs in the U.S, Europe, Asia, the Middle East, and in developing countries. Some new treatment agents can average $10K to $100K per month. Patients may suffer an out-of-pocket copayment of over $60K dollars for one chemotherapy regimen. Patients and families deal with financial toxicity and bankruptcy. There are pioneering efforts to provide data-driven analyses on cost-benefit ratios on chemotherapy regimens.
There are also greater efforts in the U.S. to incorporate the cost-benefit discussion into the patient’s decision-making and informed consent process. As the U.S. government enacts the American Health Care Act, and Medicare reimbursement changes shift to value-based payments, value initiatives are relatively new in oncology. This session will explore the value frameworks under development internationally and recent policy decisions by payers and governments to address rising costs of cancer care, increase the access to care, address the costs of cancer drugs, and reduce financial toxicity for patients and families.
The Human Development Index is a statistic that combines several indicators, including education, life expectancy, and per capita income, in order to rank countries into four tiers of human development.
10:00 – 11:00 Clinical Research & Trials
Shreya Kanodia, PhD, Samuel Oschin Comprehensive Cancer Institute
Kylie Gyertson, University College London Hospitals NHS Foundation Trust (UCLH)
Nina Spencer, MSD
This interactive session will compare and contrast management of clinical research in different countries. The discussion will focus on administrative and operational structures that develop, implement, and manage a clinical trial including staffing, budget and contract negotiations, clinical trial site evaluation and selection, marketing and advertising for recruitment, and project management, ongoing monitoring, audits and reporting. The discussions will include the value, function, authority, and regulations underlying scientific and research review boards, including protocol review committees, institutional review boards (IRBs), institutional animal care and use committees (IACUCs), radiation safety committees, biosafety committees, and data & safety monitoring boards (DSMBs).
11:15 – 12:15 From Big Data to Better Cancer Care
Andre Dekker, PhD, Maastro
Since 2008 MAASTRO Clinic (Maastricht, The Netherlands) has been embarking on a research program called Computer Assisted Theragnostics or CAT. In various CAT projects (euroCAT, duCAT, chinaCAT, ozCAT, VATE), a global IT infrastructure is developed in which cancer centers are being connected with currently 25+ partners. The aim of CAT is to enable cross-institute, privacy-preserving, data sharing & machine learning and more efficient clinical evidence generation for oncology: a concept now commonly referred to as "Rapid Learning".
In the session, innovative technology to extract, store and process (big) data for Rapid Learning and will be discussed. All this data is often seen as tremendously promising and is predicted to change health care radically, but at this point in time is mostly a challenge as we keep accumulating data without a clear path to clinical applications while privacy concerns are on the rise. Methods and examples how we go from data to making a difference in lives of cancer patients will be presented. As will the methods to do this in a way that preserves the privacy of patients.
12:15 – 14:00 Networking Luncheon
14:00 – 15:00 Through The Patient’s Eyes
Patients from US, UK and Europe to discuss their experiences with their cancer treatment, healthcare systems positives and negatives
Nancy Bookbinder, Oncology Resource Consultants, Inc.
17:00 - 18:00 Closing Reception